The study design offers one possible explanation for this lack of a demonstrated benefit. “Our study was underpowered to determine whether the increases in the pCR rates seen with the addition of carboplatin and bevacizumab improves EFS or OS,” said Sikov.
“Going forward, the question is whether we want to commit the additional patients and resources necessary to answer this question or instead focus our research efforts in TNBC on other opportunities to improve outcomes,” he concluded.
Sikov WM, Berry DA, Perou CM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Presented at: 2015 San Antonio Breast Cancer Symposium; San Antonio, TX; December 8-12, 2015. Abstract: S2-05.
<<< View more from the 2015 San Antonio Breast Cancer Symposium